Soluble Decoy Receptor 3 Induces Angiogenesis by Neutralization of TL1A, a Cytokine Belonging to Tumor Necrosis Factor Superfamily and Exhibiting Angiostatic Action
| Autor: | Che-Ming Teng, Wen-Ling Su, Chia-Ron Yang, Shie-Liang Hsieh, Feng-Ming Ho, Wan-Wan Lin |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Tumor Necrosis Factor Ligand Superfamily Member 15
Cancer Research Angiogenesis medicine.medical_treatment Neovascularization Physiologic Receptors Cell Surface Biology Vascular endothelial growth inhibitor Receptors Tumor Necrosis Factor Neovascularization Mice HT29 Cells Cell Movement medicine Animals Humans RNA Messenger Cells Cultured Membrane Glycoproteins Neovascularization Pathologic Tumor Necrosis Factor-alpha Receptors Tumor Necrosis Factor Member 6b Up-Regulation Cytokine Oncology Immunology Cancer research Matrix Metalloproteinase 2 Tumor necrosis factor alpha Endothelium Vascular Decoy receptor 3 medicine.symptom Chickens Death receptor 3 Cell Division |
| Zdroj: | Cancer Research. 64:1122-1129 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | TL1A is a member of the tumor necrosis factor superfamily and plays an important role in regulating endothelial cell apoptosis. A previous study shows TL1A is able to interact with death receptor 3 and decoy receptor 3 (DcR3). Here, we demonstrate that DcR3 is able to induce angiogenesis in human umbilical vein endothelial cells (HUVECs). DcR3 promotes HUVEC proliferation and migration and up-regulates matrix metalloproteinase-2 mRNA expression and enzyme activity. Furthermore, DcR3 enhances EC differentiation into cord vascular-like structures in vitro, as well as neovascularization in vivo. The effects of DcR3 on HUVECs are also mimicked by anti-TL1A and antideath receptor 3 antibodies. In contrast, human aortic endothelial cells, which do not express TL1A, are not responsive to DcR3 treatment, including cell proliferation, migration, and angiogenic differentiation. These data demonstrate DcR3 might not only help tumor cells to escape immune surveillance but also induce angiogenesis by blocking TL1A action in endothelial cells. The pathological role of DcR3 in promoting cancer progress raises the possibility to target DcR3 for antiangiogenic therapy in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|